BC
PCRX icon

Broadfin Capital’s Pacira BioSciences PCRX Stock Holding History

Broadfin Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-166,500
Closed -$5.19M – 54
2018
Q1 		$5.19M Buy
+166,500
New +$5.93M 0.81% 35
2017
Q1 		– Sell
-150,680
Closed -$4.87M – 59
2016
Q4 		$4.87M Hold
150,680
– – 0.54% 42
2016
Q3 		$5.16M Buy
150,680
+57,300
+61% +$2.24M 0.46% 53
2016
Q2 		$3.15M Buy
+93,380
New +$4.59M 0.31% 57

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return